Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay
| Autor: | Claudio Viscoli, A M Raiola, Malgorzata Mikulska, Elisa Furfaro, Sandra Ratto, Almalina Bacigalupo, V. Del Bono |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Penicillanic Acid Aspergillosis Gastroenterology Tazobactam Vial Microbiology Mannans Galactomannan chemistry.chemical_compound Internal medicine polycyclic compounds medicine Humans False Positive Reactions Pharmacology (medical) In patient Piperacillin Pharmacology business.industry Hematopoietic Stem Cell Transplantation Galactose biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Serum samples Anti-Bacterial Agents Piperacillin Tazobactam Drug Combination Infectious Diseases chemistry Piperacillin/tazobactam bacteria business medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 67:1746-1748 |
| ISSN: | 1460-2091 0305-7453 |
| DOI: | 10.1093/jac/dks111 |
| Popis: | Objectives: Galactomannan (GM) testing is extremely useful for diagnosing invasive aspergillosis in high-risk patients, but false-positive results have been reported in patients treated with piperacillin/tazobactam. The aims of this study are to test if the recent piperacillin/tazobactam (Tazocin TM ; Pfizer) preparation still contains GM, and if serum GM positivity in haematopoietic stem cell transplant (HSCT) recipients receiving piperacillin/ tazobactam can be attributed to this treatment. Patients and methods: Serum samples obtained from 1 October 2009 to 31 October 2010 from HSCTrecipients for GM testing were analysed. The difference in the rate of positive results (defined as GM ≥0.5) in patients receiving and not receiving piperacillin/tazobactam was evaluated. Piperacillin/tazobactam vials from randomly selected batches were tested. Results: Of 1606 samples drawn in the absence of piperacillin/tazobactam therapy, 25 (1.6%) tested positive for GM versus 10 of 394 samples (2.5%) drawn while on piperacillin/tazobactam (P ¼0.18). The median GM result of samples drawn on piperacillin/tazobactam was slightly higher than that of samples drawn in the absence of piperacillin/tazobactam (0.141 versus 0.122; P,0.001). All 90 piperacillin/tazobactam vials from 30 randomly selected batches tested negative for GM, with a median GM value of 0.057 (range: 0.011‐0.320). Conclusions: Although some residual GM might still be present in piperacillin/tazobactam, currently available brand piperacillin/tazobactam preparations seem no longer responsible for false-positive GM results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|